Strategies for Developing Biomarkers of Heart Failure

Clinical Chemistry

Volumn 50, Issue 2, 2004, Pages 265-278

  Jortani, Saeed A ^a   Prabhu, Sumanth D ^a   Valdes Jr , Roland ^a  

^a University of Louisville School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENOMEDULLIN; AMINO ACID; ATRIAL NATRIURETIC FACTOR; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; CARDENOLIDE; CARDIOTONIC AGENT; CYTOKINE; DIGITALIS LIKE FACTOR; HORMONE; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 6; NATRIURETIC FACTOR; NATRIURETIC PEPTIDE TYPE C; NEUROHORMONE; STEROID; TROPONIN; TUMOR NECROSIS FACTOR ALPHA;

ACUTE DISEASE; ADRENAL CORTEX; AMINO ACID COMPOSITION; AUTOCRINE EFFECT; BIOCHEMISTRY; CHRONIC DISEASE; CLINICAL FEATURE; CYTOKINE RELEASE; DEMOGRAPHY; DISEASE COURSE; DISEASE PREDISPOSITION; EARLY DIAGNOSIS; ENDOCRINE SYSTEM; ENDOTHELIUM CELL; HEALTH CARE COST; HEART; HEART FAILURE; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE; HEART MUSCLE CELL; HEART MUSCLE INJURY; HOMEOSTASIS; HUMAN; HYPOTHALAMUS; IMMUNOASSAY; MACROPHAGE; MAMMAL; MEDLINE; MOLECULAR BIOLOGY; NONHUMAN; PARACRINE SIGNALING; PATHOPHYSIOLOGY; PHYSIOLOGY; PREDICTION; PREVALENCE; PROGNOSIS; PROTEIN DEGRADATION; PROTEIN STRUCTURE; REGULATORY MECHANISM; REVIEW; T LYMPHOCYTE;

ANIMALS; BIOLOGICAL MARKERS; CARDIAC GLYCOSIDES; CYTOKINES; HEART FAILURE, CONGESTIVE; HUMANS; MYOCARDIUM; NATRIURETIC PEPTIDES; PROGNOSIS;

EID: 0742287013     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1373/clinchem.2003.027557     Document Type: Review

References (120)

1. Davis RC, Hobbs FDR, Lip GYH. Clinical review: ABC of heart failure. BMJ 2000;320:39-42.
2. McDermott MM, Feinglass J, Lee PI, Mehta S, Schmitt B, Lefevre F, et al. Systolic function, readmission rates, and survival among consecutively hospitalized patients with congestive heart failure. Am Heart J 1997;134:728-36.
3. Rich MW. Heart failure. Cardiol Clin 1999;17:123-35.
4. He J, Ogden LG, Bazzano LA, Loria C, Whelton PK. Risk factors for congestive heart failure in US men and women: NHANES I epidemiologic follow-up study. Arch Intern Med 2001;161:996-1002.
5. Minino AM, Smith BL. Deaths: Preliminary data for 2000. Natl Vital Stat Rep 2001;49:1-40.
6. Colucci WS, Braunwald E. Pathophysiology of heart failure. In: Braunwald E, Zipes DP, and Libby P, eds. Heart disease: a textbook of cardiovascular medicine, 6th ed. Philadelphia: WB Saunders, 2001:503-33.
7. Hunt SA, Baker DW, Chin MH, Cinquegrani MP, Feldman AM, Francis GS, et al. American College of Cardiology. American Heart Association. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary. J Heart Lung Transplant 2002;21:189-203.
8. Guthery D, Schumann L. Congestive heart failure. J Am Acad Nurse Pract 1988;10:31-41.
9. Pathenakis FI, Kanoupakis EM, Kochiadakis GE, Skalidis EI, Mezilis NE, Simantirakis EN, et al. Left ventricular diastolic filling pattern predicts cardiopulmonary determinants of functional capacity in patients with congestive heart failure. Am Heart J 2000;140:338-44.
10. Hunt SA, Baker DW, Chin MH, Cinquegrani MP, Feldman AM, Francis GS, et al. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary: a report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines (Committee to revise the 1995 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol 2001;38:2101-13.
11. Jessup M, Brozena S. Medical progress: heart failure. N Engl J Med 2003;348:2007-18.
12. Mann DL. Mechanisms and models in heart failure: a combinatorial approach. Circulation 1999;100:999-1008.
13. Hunter JJ, Chien KR. Signaling pathways for cardiac hypertrophy and failure. N Engl J Med 1999;341:1276-83.
14. Prabhu SD, Freeman GL. Effect of tachycardia heart failure on the restitution of left ventricular function in closed-chest dogs. Circulation 1995;91:176-85.
15. Pieske B, Kretschmann B, Meyer M, Holubarsch C, Weirich J, Posival H, et al. Alterations in intracellular calcium handling associated with the inverse force-frequency relation in human dilated cardiomyopathy. Circulation 1995;92:1169-78.
16. Bristow MR. Mechanism of action of β-blocking agents in heart failure. Am J Cardiol 1997;80:26L-40L.
17. Prabhu SD, Freeman GL. Altered LV inotropic reserve and mechanoenergetics early in the development of heart failure. Am J Physiol 2000;278:H698-705.
18. Fung ET, Wright GL Jr, Dalmasso EA. Proteomic strategies for biomarker identification: progress and challenge. Curr Opin Mol Ther 2000;2:643-50.
19. Slate EH, Turnbull BW. Statistical models for longitudinal biomarkers of disease. Stat Med 2000;19:617-37.
20. Alpert JS, Thygesen K, Antman E, Bassand JP. Myocardial infarction redefined - a consensus document of The European Society of Cardiology/American College of Cardiology Committee for redefinition of myocardial infarction. J Am Coll Cardiol 2000; 36:959-69.
21. Daggubati S, Parks JR, Overton RM, Cintron C, Schocken DD, Vesely DL. Adrenomedullin, endothelin, neuropeptide Y, atrial, brain, and C-natriuretic prohormone peptides compared as early heart failure indicators. Cardiovasc Res 1997;36:246-55.
22. de Bold AJ, Borenstein HB, Veress AT, Sonnenberg H. A rapid and potent natriuretic response to intravenous injection of atrial myocardial extracts in the rats. Life Sci 1981;28:89-94.
23. Sonnenberg H, Cupples WA, de Bold AJ, Veress AT. lntrarenal localization of the natriuretic effect of cardiac atrial extract. Can J Physiol Pharmacol 1982;60:1149-52.
24. Sudoh T, Kangawa K, Minamino N, Matsuo H. A new natriuretic peptide in porcine brain. Nature 1988;332:78-81.
25. Yoshibayashi M, Yoshihiko S, Nakao K. Brain natriuretic peptide versus atrial natriuretic peptide-physiological and pathophysiological significance in children and adults: a review. Eur J Endocrinol 1996;135:265-8.
26. Clerico A, Del Ry S, Giannessi D. Measurement of cardiac natriuretic hormones (atrial natriuretic peptide, brain natriuretic peptide, and related peptides) in clinical practice: the need for a new generation of immunoassay methods. Clin Chem 2000;46: 1529-34.
27. Wu AHB. B-type natriuretic peptide and its clinical utility in patients with heart failure. Med Lab Observer 2001;33:10-9.
28. Mair J, Hammerer-Lercher A, Puschendorf B. The impact of cardiac natriuretic peptide determination on the diagnosis and management of heart failure. Clin Chem Lab Med 2001;39:571-88.
29. Sarzani R, Dessi-Fulgheri P, Paci VM, Espinosa E, Rappelli A. Expression of natriuretic peptide receptors in human adipose and other tissues. J Endocrinol Invest 1996;19:581-5.
30. Nagase M, Katafuchi T, Hirose S, Fujita T. Tissue distribution and localization of natriuretic peptide receptor subtypes in stroke-prone spontaneously hypertensive rats. J Hypertens 1997;15: 1235-43.
31. Chen HH, Bumett JC Jr. The natriuretic peptides in heart failure: diagnostic and therapeutic potentials. Proc Assoc Am Physicians 1999;111:406-16.
32. Yan W, Wu F, Morser J, Wu Q. Corin, a transmembrane cardiac serine protease, acts as a pro-atrial natriuretic peptide-converting enzyme. Proc Natl Acad Sci U S A 2000;97:8525-9.
33. Cody RJ, Atlas SA, Laragh JH, Kubo SH, Covit AB, Rayman KS, et al. Atrial natriuretic factor in normal subjects and heart failure patients. Plasma levels and renal, hormonal and hemodynamic response to peptide infusion. J Clin Invest 1986;78:1362-74.
34. Muders F. Komer EP, Griese DP, Pfeifer M, Hense HW, Gunter AJ, et al. Elevation of plasma natriuretic peptides as markers for left ventricular dysfunction. Am Heart J 1997;134:442-9.
35. Lerman A, Gibbons RJ, Rodeheffer RJ, Bailey KR, McKinely LJ, Heublein DM, et al. Circulating N-terminal arterial natriuretic peptide as a marker for symptomless left-ventricular dysfunction. Lancet 1993;341:1105-9.
36. Andersson B, Hall C. N-terminal proatrial natriuretic peptide and prognosis in patients with heart failure and preserved systolic function. J Card Fail 2000;6:208-13.
37. Hammerer-Lercher A, Neubauer E, Muller S, Pachinger O, Puschendorf B, Mair J. Head-to-head comparison of N-terminal pro-brain natriuretic peptide, brain natriuretic peptide and N-terminal pro-trial natriuretic peptide in diagnosing left ventricular dysfunction. Clin Chim Acta 2001;310:193-7.
38. Bay M, Kirk V, Parner J, Hassager C, Nielsen H, Krogsgaard K, et al. NT-proBNP: a new diagnostic screening tool to differentiate between patients with normal and reduced left ventricular systolic function. Heart 2003;89:150-4.
39. Lubien E, DeMaria A, Krishnaswamy P, Clopton P, Koon J, Kazanegra R, et al. Utility of B-natriuretic peptide in detecting diastolic dysfunction: comparison with Doppler velocity recordings. Circulation 2002;105:595-601.
40. Sodian R, Loebe M, Schmit C, Potapov EV, Sinawski H, Muller J, et al. Decreased plasma concentrations of brain natriuretic peptide as a potential indicator of cardiac recovery in patients supported by mechanical circulatory assist system. J Am Coll Cardiol 2001;38:1942-9.
41. Crilley JG, Farrer M. Left ventricular remodeling and brain natriuretic peptide after first myocardial infarction. Heart 2001;86: 638-42.
42. De Lemos, JA, Morrow DA, Bentley JH, Omland T, Sabatine MS, McCabe CH, et al. The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N Engl J Med 2001;345:1014-21.
43. Maisel AS, McCord J, Nowak RM, Hollander JE, Wu AH, Due P, et al. Bedside B-type natriuretic peptide in the emergency diagnosis of heart failure with reduced or preserved ejection fraction. Results from the Breathing Not Properly Multinational Study. J Am Coll Cardiol 2003;41:2010-7.
44. BioSite Diagnostics Incorporated. Triage BNP test for rapid quantification of B-type natriuretic peptide [Package Insert]. San Diego, CA: BioSite Diagnostics Incorporated, 1999:1-23.
45. Clerico A, Del Ry S, Maffei S, Prontera C, Emdin M, Giannessi D. The circulating levels of cardiac natriuretic hormones in healthy adults: effects of age and sex. Clin Chem Lab Med 2002;40: 371-7.
46. Vogeser M, Jacob K. B-type natriuretic peptide (BNP) - validation of an immediate response assay. Clin Lab 2001;47:29-33.
47. Maeda K, Tsutamoto T, Wada A, Hisanaga T, Kinoshita M. Plasma brain natriuretic peptide as a marker of high left ventricular end-diastolic pressure in patients with symptomatic left ventricular dysfunction. Am Heart J 1998;135:825-32.
48. Goetze JP, Kastrup J, Pedersen F, Rehfeld JF. Quantification of pro-B-type natriuretic peptide and its products in human plasma by use of an analysis independent of precursor processing. Clin Chem 2002;48:1035-42.
49. Qazzaz HMAM, El-Masri A, Valdes R Jr. Secretion of a lactone- hydrogenated ouabain-like effector of sodium, potassium-adenosine triphosphate activity by adrenal cells. Endocrinology 2000;141:3200-9.
50. Qazzaz HMAM, Jortani SA, Poole JM, Valdes R Jr. Evidence for presence of a reduced form of digoxin-like immunoreactive factor (Dihydro-DLIF) in mammalian tissues. Clin Chem 1996;42:1092-9.
51. Jortani SA, Valdes R Jr. Mammalian cardenolides as biomarkers in congestive heart failure. Cardiovasc Toxicol 2001;1:165-70.
52. Schoner W. Endogenous cardiotonic steroids. Cell Mol Biol 2001;47:273-80.
53. Jortani SA, Valdes R. Digoxin and related endogenous factors. Crit Rev Clin Lab Sci 1996;34:225-74.
54. Lin MH, Loao CP, Lee JS, Chin YW, Hsu CC, Wei JS. Detection of endogenous digitalis-like immunoreactive factor in human blood. Proc Natl Sci Counc Repub China B 1988;22:129-35.
55. Liu ZQ, Ma AQ, Zhang L, Yang DY. Intra-cellular electrolyte changes and levels of endogenous digoxin-like substances within the plasma in patients with congestive heart failure. Int J Cardiol 1990;27:47-53.
56. Bundgaard H, Kjeldsen K. Human myocardial Na,K-ATPase concentration in heart failure. Mol Cell Biochem 1996;163:277-83.
57. Lingrel JB, Kuntzweiler T. Na+,K(+)-ATPase. J Biol Chem 1994; 269:19659-62.
58. Levi AJ, Boyett MR, Chin OL. The cellular actions of digitalis glycosides on the heart. Prog Biophys Mol Biol 1994;62:1-54.
59. +-ATPase. J Biol Chem 2000;275:27832-7.
60. +-ATPase to hypertrophy and its maker genes in cardiac myocytes. J Biol Chem 1999;274:19323-8.
61. Leenen FHH, Huang BS, Yu H, Yuan B. Brain 'ouabain' mediates sympathetic hyperactivity in congestive heart failure. Circ Res 1995;77:993-1000.
62. Allen PD, Schmidt TA, Marsh JD, Kjeldsen K. Na,K-ATPase expression in normal and failing human left ventricle. Basic Res Cardiol 1992;87:87-94.
63. Balzan S, Neglia D, Ghione S, D'Urso G, Baldacchino MC, Montali U, et al. Increased circulating levels of ouabain-like factor in patients with asymptomatic left ventricular dysfunction. Eur J Heart Fail 2001;3:165-71.
64. Gottlieb SS, Rogowski AC, Weinberg M, Krichten CM, Hamilton BP, Hamlyn JM. Elevated concentrations of endogenous ouabain in patients with congestive heart failure. Circulation 1992;86: 420-5.
65. Fridman Al, Matveev SA, Agalakova NI, Fedorova OV, Lakatta EG, Bagrov AY. Marinobufagenin, an endogenous ligand of α-1 sodium pump, is a marker of congestive heart failure severity. J Hypertens 2002;20:1189-94.
66. +)-ATPase in rat cardiac hypertrophy. J Biol Chem 1986;261:185-9.
67. Mansier P, Chevalier B, Mayoux E, Charlemagne D, Ollivier L, Callens-el Amrani F, et al. Membrane proteins of the myocyte in cardiac overload. Br J Clin Pharmacol 1990;30:43S-8S.
68. Velotta WJ, McDonugh AA, Farley RA. All human Na(+)-K(+)-ATPase α-subunit isoforms have a similar affinity for cardiac glycosides. Am J Physiol Cell Physiol 2001;281:1336-43.
69. + concentration is elevated in heart failure but Na/K pump function is unchanged. Circulation 2002;105:2543-8.
70. Szekanecz Z, Koch AE. Cytokines. In: Ruddy S, ed. Kelley's textbook of rheumatology, 6th ed. St. Louis, MO: WB Saunders, 2001:275-88.
71. Tramont EC, Hoover DL. Innate (general or nonspecific) host defense mechanisms. In: Mandell GE, Bennett JE, Dolin R, eds. Principles and practice of infectious diseases, 5th ed. Orlando, FL: Churchill Livingstone, Inc., 2000:31-8.
72. Finkel MS, Oddis CV, Jacob TD, Watkins SC, Hattler BG, Simmons RL. Negative inotropic effects of cytokines on the heart mediated by nitric oxide. Science 1992;257:387-9.
73. Yokoyama T, Nakano M, Bednarczyk JL, McIntyre BW, Entman M, Mann DL. Tumor necrosis factor-α provokes a hypertrophic growth response in adult cardiac myocytes. Circulation 1997;95: 1247-52.
74. Krown KA, Page MT, Nguyen C, Zechner D, Gutierrez V, Comstock KL, et al. Tumor necrosis factor α-induced apoptosis in cardiac myocytes. Involvement of the sphingolipid signaling cascade in cardiac cell death. J Clin Invest 1996;98:2854-65.
75. Bradham WS, Moe G, Wendt KA, Scott AA, Konig A, Romanova M, et al. TNF-α and myocardial matrix metalloproteinases in heart failure: relationship to LV remodeling. Am J Physiol Heart Circ Physiol 2002;282:H1288-95.
76. Hensley K, Robinson KA, Gabbita SP, Salsman S, Floyd RA. Reactive oxygen species, cell signaling, and cell injury. Free Radic Biol Med 2000;28:1456-62.
77. Adamopoulos S, Parissis JT, Kremastinos DT. A glossary of circulating cytokines in chronic heart failure. Eur J Heart Fail 2001;3:517-26.
78. Steele IC, Nugent AM, Maguire S, Hoper M, Campbell G, Halliday MI, et al. Cytokines in chronic cardiac failure. Eur J Clin Invest 1996;26:1018-22.
79. Testa M, Yeh M, Lee P, Fanelli R, Loperfido F, Berman JW, et al. Circulating levels of cytokines and their endogenous modulators in patients with mild to severe congestive heart failure due to coronary artery disease or hypertension. J Am Coll Cardiol 1996;28:964-71.
80. Conraads VM, Bosmans JM, Vrints CJ. Chronic heart failure: an example of a systemic chronic inflammatory disease resulting in cachexia. Int J Cardiol 2002;85:33-49.
81. Francis SE, Holden H, Holt CM, Duff GW. Interleukin-1 in myocardium and coronary arteries of patients with dilated cardiomyopathy. J Mol Cell Cardiol 1998;30:215-23.
82. Prabhu SD, Chandrasekar B, Murray DR, Freeman GL. βAdrenergic blockade in developing heart failure: effects on myocardial inflammatory cytokines, nitric oxide, and remodeling. Circulation 2000;101:2103-9.
83. Murray DR, Prabhu SD, Chandrasekar B. Chronic β-adrenergic stimulation induces myocardial proinflammatory cytokine expression. Circulation 2000;101:2338-41.
84. Bristow MR. β-Adrenergic receptor blockade in chronic heart failure. Circulation 2000;101:558-69.
85. Werner C, Werdan K, Ponicke K, Brodde OE. Impaired βadrenergic control of immune function in patients with chronic heart failure: reversal by β1-blocker treatment. Basic Res Cardiol 2001;96:290-8.
86. Feldman AM, Combes A, Wagner D, Kadakomi T, Kubota T, Li YY, et al. The role of tumor necrosis factor in pathophysiology of heart failure. J Am Col Cardiol 2000;35:537-44.
87. Roig E, Orus J, Pare C, Azqueta M, Filella X, Perez-Villa F, et al. Serum interleukin-6 in congestive heart failure secondary to idiopathic dilated cardiomyopathy. Am J Cardiol 1998;82:688-90.
88. Raymond RJ, Dehmer GJ, Theoharides T, Deliargyris EN. Elevated interleukin-6 levels in patients with asymptomatic left ventricular systolic dysfunction. Am Heart J 2001;141:435-8.
89. Caforio AL, Goldman JH, Baig MK, Mahon NJ, Haven AJ, Souberbielle BE, et al. Elevated serum levels of soluble interleukin-2 receptor, neopterin and β-2-microglobulin in idiopathic dilated cardiomyopathy: relation to disease severity and autoimmune pathogenesis. Eur J Heart Fail 2001;3:155-63.
90. Carswell EA, Old LJ, Kassel RL, Green S, Fiore N, Williamson B. An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci U S A 1975;72:3666-70.
91. Yoshida A, Kand T, Tanaka T, Yokoyama T, Kurimoto M, Tamura J, et al. Interleukin-18 reduces expression of cardiac tumor necrosis factor-a and atrial natriuretic peptide in marine model of viral myocarditis. Life Sci 2002;70:1225-34.
92. Levine B, Kalman J, Mayer L, Fillit HM, Packer M. Elevated circulating levels of tumor necrosis factor in severe congestive heart failure. N Engl J Med 1990;323:236-41.
93. Zhao SP, Zeng LH. Elevated plasma levels of tumor necrosis factor in chronic heart failure with cachexia. Int J Cardiol 1997; 58:257-61.
94. Cicoira M, Bolger AP, Doehner W, Rauchhaus M, Davos C, Sharma R, et al. High tumour necrosis factor-α levels are associated with the exercise intolerance and neurohormonal activation in chronic heart failure patients. Cytokine 2001;15: 80-6.
95. Larsen Al, Pal A, Aarsland T, Dickstein K. Effect of aerobic exercise training on plasma levels of tumor necrosis factor a in patients with heart failure. Am J Cardiol 2001;88:805-8.
96. Birks EJ, Burton PBJ, Owen V, Mullen AJ, Hunt D, Banner NR, et al. Elevated tumor necrosis factor-α and interleukin-6 in myocardium and serum of malfunctioning donor hearts. Circulation 2000;102:352-8.
97. Liu L, Zhao SP. The changes of circulating tumor necrosis factor levels in patients with congestive heart failure influenced by therapy. Int J Cardiol 1999;69:77-82.
98. Mann DL. Recent insights into the role of tumor necrosis factor in the failing heart. Heart Fail Rev 2001;6:71-80.
99. Kubota T, Miyagishima M, Alvarez RJ, Kormos R, Rosenblum WD, Demetris AJ, et al. Expression of proinflammatory cytokines in the failing human heart: comparison of recent onset and endstage congestive heart failure. J Heart Lung Transplant 2000; 19:819-24.
100. McGowan GA, Mann DL, Kormos RL, Feldman AM, Murali S. Circulating interleukin-6 in severe heart failure. Am J Cardiol 1997;79:1128-31.
101. Abdallah AN, Billes MA, Attia Y, Doutermepuich C, Cassaigue A, Iron A. Evaluation of plasma levels of tumor necrosis factor a and interleukin-6 as rejection markers in a cohort of 142 heart-grafted patients followed by endomyocardial biopsy. Eur Heart J 1997;18:885-6.
102. Tsutamoto T, Hisanaga T, Wada A, Maeda K, Ohnishi M, Fukai D, et al. Interleukin-6 spillover in the peripheral circulation increases with the severity of heart failure, and the high plasma level of interleukin-6 is an important prognostic predictor in patients with congestive heart failure. J Am Coll Cardiol 1998; 31:391-8.
103. Kreuzer KA, Rockstroh JK, Sauerbruch T, Spengler U. A comparative study of different enzyme immunosorbent assays for human tumor necrosis factor-α. J Immunol Methods 1996;195: 49-54.
104. Masson S, Latini R, Bevilacqua M, Vago T, Sessa F, Torri M, et al. Within-patient variability of hormone and cytokine concentrations in heart failure. Pharmacol Res 1998;37:213-7.
105. Missov E, Calzolari C, Pau B. Circulating cardiac troponin I in severe congestive heart failure. Circulation 1997;96:2953-8.
106. Del Carlo CH, O'Connor CM. Cardiac troponins in congestive heart failure. Am Heart J 1999;138:646-53.
107. Missov E, Mair J. A novel biochemical approach to congestive heart failure: cardiac troponin T. Am Heart J 1999;138:95-9.
108. Jougasaki M, Rodeheffer RJ, Redfield MM, Yamamoto K, Wei CM, McKinley, et al. Cardiac secretion of adrenomedullin in human heart failure. J Clin Invest 1996;97:2370-6.
109. Jougasaki M, Stevens TL, Borgeson DD, Luchner A, Redfield MM, Burnett JC Jr. Adrenomedullin in experimental congestive heart failure: cardiorenal activation. Am J Phys 1997;273: 1392-9.
110. Filippatos GS, Tsilias K, Venetsanou K, Karambins E, Manolatos D, Kranidis A, et al. Leptin serum levels in cachectic heart failure patients. Relationship with tumor necrosis factor-a system. Int J Cardiol 2000;76:117-22.
111. Cugno M, Agostoni P, Brunner HR, Gardinali M, Agostoni A, Nussberger J. Plasma bradykinin levels in human chronic congestive heart failure. Clin Sci 2000;99:461-6.
112. El-Aroussy W, Rizk A, Mayhoub G, Aleem SA, El-Tobgy S, Mokhtar MS. Plasma carnitine levels as a marker of impaired left ventricular functions. Mol Cell Biochem 2000;213:37-41.
113. O'Connor CM, Gurbel PA, Serebruany VL. Usefulness of soluble and surface-bound P-selectin in detecting heightened platelet activity in patients with congestive heart failure. Am J Cardiol 1999;83:1345-9.
114. Ueno S, Ikeda U, Hojo Y, Arakawa H, Nonaka M, Yamamoto K, Shimada K. Serum hepatocyte growth factor levels are increased in patients with congestive heart failure. J Card Fail 2001;7: 329-34.
115. Clark DJ, Cleman MW, Pfau SE, Rollins SA, Ramahi TM, Mayer C, et al. Serum complement activation in congestive heart failure. Am Heart J 2001;141:684-90.
116. Ogino K, Ogura K, Kinugasa Y, Furuse Y, Uchida K, Simoyama M, et al. Parathyroid hormone-related protein is produced in the myocardium and increased in patients with congestive heart failure. J Clin Endocrinol Metab 2002;87:4722-7.
117. Lommi J, Kupari M, Koskinen P, Naveri H, Leinonen H, Pulkki K, et al. Blood ketone bodies in congestive heart failure. J Am Coll Cardiol 1996;28:665-72.
118. Asakura S, Tabei K, Muto S, Asano Y, Hosoda S. The role of endogenous dopamine in congestive heart failure. Jpn Heart J 1989;30:115-27.
119. Oya H, Nagaya N, Furuichi S, Nishikimi T, Ueno K, Nakanishi N, et al. Comparison of intravenous adrenomedullin with atrial natriuretic peptide in patients with congestive heart failure. Am J Cardiol 2000;86:94-8.
120. Keeling KL, Jortani SA, Womack PW, Valdes R Jr. Measurement of endogenous dihydroouabain-like factor (Dh-OLF) in heart failure patients [Abstract]. Clin Chem 2003;49:A69.